药物对比
Sotagliflozin vs Troglitazone
比较Sotagliflozin（Inpefa）双重SGLT1/2抑制剂与已撤市的TZD类药物Troglitazone治疗糖尿病。在心血管获益、肝脏安全性和使用方面的差异。
此页面暂无可用的对比维度。
临床背景
This comparison is triggered when evaluating discontinued thiazolidinediones against current dual SGLT inhibitors for type 2 diabetes and cardiovascular risk.
结论
Sotagliflozin is the available dual SGLT inhibitor option, unlike withdrawn Troglitazone which carried unacceptable liver risks.
全部药物对比